← Back to Search

Artificial Intelligence

Participants with long COVID and respiratory symptoms for COVID-19

N/A

Recruiting

Research Sponsored by MaxWell Clinic, PLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 days

Awards & highlights

Study Summary

This trial aims to see if artificial intelligence can differentiate between specific blood RNA from patients with long COVID and those without, as well as from other medical conditions that have similar symptoms to long COVID.

Who is the study for?

This trial is for individuals who have long COVID symptoms. It's designed to see if a blood test can identify unique RNA markers of the condition. Participants should be those experiencing long COVID or with similar symptoms due to other conditions.Check my eligibility

What is being tested?

The study is testing whether an AI-driven blood test that looks at RNA biomarkers can accurately distinguish between long COVID and other illnesses with similar symptoms, as well as healthy individuals.See study design

What are the potential side effects?

Since this trial involves a non-invasive blood test, side effects are minimal and may include temporary discomfort or bruising at the needle site.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Artificial Intelligence Identified number of RNA Biomarkers for Long COVID

Secondary outcome measures

Artificial Intelligence Identified number of RNA Biomarkers for specific Long COVID subgroups

Trial Design

11Treatment groups

Active Control

Group I: Participants with long COVID and respiratory symptomsActive Control1 Intervention

Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with their respiratory system: continued shortness of breath, etc.. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group II: Respiratory symptoms prior to 1 November 2019 without history of SARS-COV-2 infectionActive Control1 Intervention

Participants without a history of SARS-COV-2 infection who had respiratory symptoms prior to 1 November 2019. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group III: Participants with SARS-COV-2 post-infection without long COVIDActive Control1 Intervention

Participants with a history of SARS-COV-2 infection, but never developed long term sequalae. This is a control arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group IV: Participants who have long COVID with both respiratory and neurological symptomsActive Control1 Intervention

Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with both their respiratory system and their neurologic system. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group V: Participants never infected by SARS-COV-2Active Control1 Intervention

Participants with no history of SARS-COV-2 infection. This is a control arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group VI: Participants who do not meet long COVID criteria but are otherwise unclassifiedActive Control1 Intervention

Participants with a history of SARS-COV-2 infection who do not have signs of Long COVID but do not fit into other arms.

Group VII: Participants with long COVID and neurological symptomsActive Control1 Intervention

Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with their neurologic system: brain fog, confusion, etc.. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group VIII: Participants who have other long COVID symptomsActive Control1 Intervention

Participants with a history of SARS-COV-2 infection and developed long term sequalae not associated with their respiratory system and their neurologic system. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group IX: Participants with neurological symptoms prior to 1 November 2019Active Control1 Intervention

Participants with a history of SARS-COV-2 infection who had neurologic symptoms prior to 1 November 2019. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group X: Participants with respiratory symptoms prior to 1 November 2019Active Control1 Intervention

Participants with a history of SARS-COV-2 infection who had respiratory symptoms prior to 1 November 2019. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Group XI: Neurological symptoms prior to 1 November 2019 without history of SARS-COV-2 infectionActive Control1 Intervention

Participants without a history of SARS-COV-2 infection who had neurologic symptoms prior to 1 November 2019. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

MaxWell Clinic, PLCLead Sponsor

1 Previous Clinical Trials

43 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of subjects being examined in this particular research investigation?

"Indeed, data available on clinicaltrials.gov confirms that this investigation is actively enrolling participants. The trial was initially posted on March 15th, 2024 and most recently revised on March 14th, 2024. This clinical trial aims to recruit a total of 3000 individuals at one specific site."

Answered by AI

Are there any available openings for patients to participate in this medical study?

"As per clinicaltrials.gov, this research is currently in the recruitment phase. The trial was first listed on March 15th, 2024, and its most recent update was on March 14th of the same year."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

Cale T Queen 2024. "Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06311435.

All > Survivor Corps > Nashville